Updated Outcome and Treatment Benefit Data from MINDACT Study Reinforce Real-World Value of MammaPrint® for Clinical Low Risk Breast Cancer Patients at SABCS 2020
IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)– Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that additional data from its groundbreaking MINDACT...